CClinicalTrials.gg
RecruitingNCT07574502Updated Aug 14, 2026

Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients

An interventional study of TEA and sham-TEA in Colorectal Cancer (CRC), sponsored by Sir Run Run Shaw Hospital. Recruiting at 2 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to clarify the efficacy and safety of transcutaneous electrical acustimulation (TEA) in elderly patients with colorectal cancer, and to evaluate its clinical value in promoting postoperative intestinal function recovery and reducing the incidence of intestinal complications. The main questions it aims to answer are:

Can TEA promote the recovery of intestinal function in elderly patients with colon cancer after surgery? What medical problems might occur to the participants when using TEA? The researchers will compare TEA with the control group (non-acupoint sham stimulation) to see if TEA is effective in promoting the recovery of intestinal function after surgery.

Participants will:

Starting from the first day after the surgery, they received TEA or sham stimulation twice a day for a total of 3 days.

Record the time of the first defecation, defecation, and eating. Record their symptoms and adverse events.

02

Conditions studied

  • Colorectal Cancer (CRC)
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 65 years old.
  • Elective minimally invasive (laparoscopic or robotic) resection of colorectal cancer.
  • American Society of Anesthesiologists classification (ASA) 1-4.
  • Able to understand the research process and the use of various assessment scales, and able to communicate effectively with the researchers.
  • The patient voluntarily participates in this study and signs the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Previous history of abdominal gastrointestinal surgery.
  • Planned for palliative or emergency surgery.
  • Planned for open abdominal surgery or creation of a new stoma.
  • Transfer to ICU.
  • Diagnosed with severe heart, liver, kidney or mental system diseases.
  • Patients with implanted cardiac pacemakers.
  • Patients currently using or having used in the past month glucagon-like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
  • Planned to use epidural anesthesia or epidural analgesia.
  • Presence of local skin lesions, infection at the stimulation site, or obvious skin allergy or severe skin sensitivity to electrodes/adhesive materials.
  • Participated in other clinical studies within the past 3 months or received acupuncture treatment within the past month.
  • Other conditions that the investigator considers make the patient unsuitable for participation in this study.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    TEA

    Device: TEA

  • Sham comparator
    sham-TEA

    Device: sham-TEA

Interventions

  • DeviceTEA

    The subjects in the TEA group were placed in the supine position and received transcutaneous electrical acupoint stimulation at the bilateral PC6 and bilateral ST36 . After confirming the location of the acupoints , special skin treatment was carried out. The stimulation parameters for PC6 were set as follows: 0.1 seconds of opening stimulation, 0.4 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 100 Hz, and amplitude ranging from 1 to 10 mA (based on the maximum level that the subject could tolerate). The stimulation parameters for ST36 were set as follows: 2 seconds of opening stimulation, 3 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude ranging from 2 to 10 mA (based on the maximum level that the subject could tolerate).

  • Devicesham-TEA

    Sham-TEA was the same except that non-acupoints were used to replace ST36 and PC6. The sham-acupoint for PC6 was located at about 15-20 cm away from PC6 (up to the elbow and outside of the coastal margin of the forearm not on any meridian) and the sham-point for ST36 was located at 10-15 cm down from and to the lateral side of ST36 not on any meridian

05

What researchers measure

Primary outcomes

  1. Time to First Flatus

    Defined as the period from the end of the surgery to the time of first flatus (hours).

    Time frame: Assessed up to 10 days after surgery

Secondary outcomes

  1. Prolonged post operative ileus (PPOI)

    defined as no flatus for more than 72 hours

    Time frame: Assessed up to 72 hours after surgery

  2. time to first defecation

    Defined as the period from the end of the surgery to the time of first defecation (hours).

    Time frame: Assessed up to 10 days after surgery

  3. time to first water intake

    The time from the end of the surgery to the first water intake (hours)

    Time frame: Assessed up to 10 days after surgery

  4. Time to tolerance of liquid diet

    "Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after the liquid diet. Record the time (in hours) from the end of the surgery to the first tolerance to the liquid diet.

    Time frame: Assessed up to 10 days after surgery

  5. Time to tolerance of semi-liquid diet

    "Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after semi-liquid food. Record the time ( hours) from the end of the surgery to the first tolerance of semi-liquid food.

    Time frame: Assessed up to 10 days after surgery

  6. Time to tolerance of solid food

    "Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after solid food. Record the time (hours) from the end of the surgery to the first tolerance of solid food.

    Time frame: Assessed up to 10 days after surgery

  7. Time to first ambulation

    The time from the end of the surgery to the first ambulation (hours).

    Time frame: Assessed up to 10 days after surgery

  8. Postoperative nausea

    The number and frequency of postoperative nausea episodes

    Time frame: At 24, 48, and 72 hours after surgery

  9. postoperative vomiting

    The number and frequency of postoperative vomiting

    Time frame: At 24, 48, and 72 hours after surgery

  10. postoperative abdominal distension

    The number and frequency of postoperative abdominal distension

    Time frame: At 24, 48, and 72 hours after surgery

  11. Use of anti-emetic drugs after surgery

    Number of participants using antiemetic drugs

    Time frame: At 24, 48, and 72 hours after surgery

  12. Severity of postoperative pain

    The assessment was conducted using a numerical rating scale (NRS). The scoring range was 0-10 (0 indicated no pain, while 10 indicated unbearable severe pain. Scores of 1-3 indicated mild pain that could be tolerated; 4-6 indicated pain that affected sleep but was still tolerable; 7-10 indicated severe pain that affected appetite and sleep).

    Time frame: At 24, 48, and 72 hours after surgery

  13. Use of opioids drugs after surgery

    The total dosage of all opioid analgesics used within 24 hours, 48 hours, and 72 hours after surgery, converted into morphine equivalents.

    Time frame: At 24, 48, and 72 hours after surgery

  14. Postoperative quality of recovery

    Assessed using the Quality of Recovery - 15 score (QoR-15) questionnaire preoperatively and daily. The total score ranges from 0 to 150 points. The higher the score, the better the post-anesthesia recovery quality.

    Time frame: baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)

  15. TEA Security

    assessing the adverse events related to the equipment (including numbness in the hands, pain, and skin allergies)

    Time frame: Assessed up to 3 days after surgery

  16. Postoperative complications

    The severity of complications was evaluated using the Clavien-Dindo classification system (grades I to V), with Clavien-Dindo grade ≥ III complications serving as the major surgical complications.

    Time frame: From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)

  17. Total length of hospital stay

    primary admission plus any readmission up to 30 days

    Time frame: Assessed up to 30 days after surgery

  18. Unplanned readmission

    Record the number of unplanned re-admissions within 30 days of hospital discharge

    Time frame: Assessed up to 30 days after surgery

06

Study locations

1 of 2 sites recruiting
  • Shandong Medical and Pharmaceutical University Hospital
    Binzhou, Shandong, China
    Not yet recruiting
  • Sir Run Run Shaw Hospital
    Hangzhou, Zhejiang, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07574502
Lead sponsor
Sir Run Run Shaw Hospital
Responsible party
Xin Yu (professor, Sir Run Run Shaw Hospital) — Principal investigator
First posted
May 8, 2026
Start date
Jun 14, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Xin Yu
Contact
xinxin_yu@zju.edu.cn
86006663

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion